Gene therapy for endocrine diseases represents an exciting new type of molecular intervention that may be a curative one. Endocrine disorders that might be treated by gene therapy include monogenic diseases, such as GH de®ciency and hypothalamic diabetes insipidus, and multifactorial diseases, such as diabetes mellitus, obesity and cancer. Premises seem promising for endocrine tumours, but many combined approaches of cell and gene therapy are foreseeable also for other endocrine disorders. This review outlines the principles of gene therapy, describes the endocrine disorders that might take advantage of gene transfer approaches, as well as the gene therapy interventions that have already been attempted, their major limitations and the problems that remain to be solved.
Introduction
In the last three decades scienti®c progress in biomedical research has revealed the molecular mechanisms and genetic bases of many human diseases. The observation that some pathologies are caused by the inheritance of a single, functionally defective gene (monogenic diseases) generated the concept of gene-based therapy consisting of the supplementation of the defective gene with a functional one to be transferred to the affected cells.
Gene therapy, in its initial and broadest sense, can be de®ned as the transfer of a gene to a patient for therapeutic purposes. Initially developed as a strategy to treat inherited monogenic disorders by supplying the correct, wild-type copy of a mutated gene, gene therapy has gained importance as a tool to treat a growing number of human diseases. Indeed, the original concept of gene therapy as`gene supplementation' has rapidly switched to the more general one of any strategy that employs genetic material (DNA or RNA) to prevent or cure a variety of diseases, many of which do not involve germ-line mutations, including multifactorial and somatic genetic diseases, such as diabetes mellitus, obesity, hypertension and cancer.
The development of more sophisticated techniques of molecular biology has allowed us to go rapidly from theory to application, as demonstrated by the 396 gene therapy clinical trials, involving 3278 patients worldwide, which have been undertaken since the ®rst one in 1989 (data from Journal of Gene Medicine, www. wiley.co.uk/genmed, updated to 1 September 1999) (1).
Even though the disorders targeted by gene therapy approaches span the entire spectrum of human diseases, as shown in Table 1 cancer has become a major interest, with 63.6% of the ongoing protocols involving cancer patients (1).
Notwithstanding the disappointing preliminary clinical results, gene therapy has become an established concept in medicine. The future success of gene therapy relies on the progress of the basic science, in the discovery of new disease-related genes, and in the development of suitable animal models of human diseases.
As for endocrine diseases, gene therapy is still at an experimental stage, since no clinical studies have been published so far. However, signi®cant advances have been made during the last few years, and in vitro and in vivo studies suggest that several endocrine diseases could bene®t from gene therapy.
of hormone transport or metabolism, and multiple hormone abnormalities, including endocrine tumours (2). These disorders can result in either endocrine hyperfunction or hypofunction. Research progress in endocrinology has allowed the identi®cation of inherited and acquired genetic disorders, as well as the molecular bases of many endocrine diseases, opening the possibility of correcting the underlying defect. Indeed, conventional treatments of most human disorders are often focused at improving symptoms, rather than at correcting the causative defects. Notwithstanding the success of current conventional therapy, the question arises as to whether there is a true need for gene therapy of endocrine diseases. A ®rst answer could be that, in many cases, current therapeutic approaches cannot truly cure the patient, and that hormone replacement cannot always reproduce physiological hormone levels. Moreover, gene therapy may provide useful tools for the treatment of endocrine tumours and of immune-based endocrine disorders which do not respond to conventional treatments.
Different approaches of genetic intervention are foreseeable for endocrine diseases, as summarised in Fig. 1 . Strategies for gene therapy of endocrine hyperfunction require either the transfer of a gene with ameliorating effects, such as tyrosine hydroxylase in prolactinomas (3), or the inhibition of genes associated with hormone hypersecretion, by the use of antisense oligonucleotides or ribozymes. Endocrine hypofunction may require the delivery of the wild-type gene coding for the lacking hormone, such as the growth hormone (GH) gene in GH de®ciency. Immunomodulating gene therapy could be useful in the treatment of autoimmune diseases that result in either endocrine hyperfunction or hypofunction. Benign and malignant endocrine tumours would take advantage of tumour suppressor gene delivery, oncogene inhibition, anti-angiogenic approaches or suicide and immunomodulating gene therapy.
Methods of gene transfer
Gene therapy requires ef®cient delivery of nucleic acid sequences to target cells, adequate and prolonged expression of the introduced gene, without any toxic side-effects for the target tissue and for the individual as a whole. Ex vivo and in vivo approaches have been used. Ex vivo strategies require the removal of cells from the body, their transduction by viral or non-viral vectors carrying the therapeutic gene, and their reinfusion into the patient. The ex vivo approach has the advantage that safety of modi®ed cells can be evaluated before their administration to the patient. However, isolation of a suf®cient number of cells and their appropriate manipulation in culture without causing undesirable changes in their biological properties are required. In the in vivo approach the vector carrying the therapeutic gene is directly administered to the patient.
Given the identi®cation and availability of a large number of therapeutic sequences, the limiting step for a successful gene therapy is the development of an ef®cient gene transfer system to reach the target cells. With few exceptions, such as the skeletal muscle and the skin, naked DNA is not ef®ciently taken up (Table 2) .
The choice of a vector is dependent upon the target cell. In gene therapy approaches for rapidly proliferating cells, such as cancer cells, retroviral vectors are the most indicated, since they only infect dividing cells. If the target cells are quiescent, adenoviral and AAV vectors are the most suitable ones, since they infect both dividing and non-dividing cells. Another factor to be considered in choosing a vector is the size of the therapeutic gene that has to be transferred. Adenoviral vectors can accommodate up to 30 kb of foreign genes, whereas AAV vectors no more than 4.5 kb. Retroviral vectors have a gene transfer capacity of about 7±8 kb.
When a long-term expression of the therapeutic cassette is required, retroviral vectors are the most appealing ones, since they integrate into the host genome, assuring a quite stable expression. On the contrary, with adenoviral vectors, whose genome is carried extra-chromosomally, repeated administrations are necessary to obtain a sustained expression. The immune response against adenoviral vectors, which is driven by the expression of viral proteins, and the need for repeated administrations, can be deleterious in those cases when stable transgene expression is required; in some others, as in cancer gene therapy, it may prove useful, helping in tumour recognition and killing.
A major limitation of the gene transfer systems so far developed is the dif®culty in obtaining clinically relevant levels of gene expression. Moreover, no single vector has emerged as being optimal for all applications. Current systems differ in their suitability for ex vivo versus in vivo adoption, their capability for persistent gene expression, and for the induction of toxicity. Each of the different vector systems presents advantages and disadvantages, which depend also on the disease that has to be treated. An ideal vector containing all the possible components to overcome the barriers to gene delivery is depicted in Fig. 2 .
Targeted gene therapy in endocrinology
An important issue in the development of gene therapy protocols is the need to target therapeutic gene delivery. Indeed, safety is a primary concern of gene therapy, and targeted vectors are required both to minimise the risk of germ-line cell transduction and to prevent sideeffects to the surrounding healthy tissues. Moreover, targeting can reduce vector wastage, and the amount of vector stocks that need to be produced and administered in vivo in order to achieve therapeutic levels of transduction.
Targeting of vectors can be obtained in many ways. The easiest one is to deliver the vector directly at the target site. For systemic administration molecular engineering is required to target either gene expression or gene delivery. A transcriptional targeting can be attempted by the introduction of tissue-speci®c or tumour-speci®c enhancers/promoters to control the expression of the therapeutic genes. Targeted gene delivery may be achieved also by the exploitation of the natural tropism shown by some viruses for speci®c tissues (e.g. hepatitis virus for liver cells), or by modi®cation of the viral tropism (viral envelope pseudotyping; expression of antibodies or ligands on the viral particle surface to confer new binding speci®city towards target cell receptors).
Endocrine glands appear to favour targeted gene therapy at different levels: (i) the easily accessible anatomical site of some endocrine glands (thyroid, pituitary) allows the direct inoculation of the vector, and the evaluation of cell transduction; and (ii) transcriptional control elements (enhacer/promoter) for the expression of tissue-speci®c genes (hormones, hormone receptors) may be employed to selectively direct transgene expression (Table 3) ; and (iii) tissue-speci®c surface proteins (such as hormone receptors) may be used as targets for vectors with modi®ed tropism.
Targeted gene correction in endocrinology
Gene therapy has been traditionally conceived as gene supplementation', an approach in which the have employed a gene supplementation approach. However, this strategy has some limits: (i) the gene is often too large and has complex regulatory sequences, so that it cannot be introduced into a vector system; (ii) in some cases, host immune responses against the viral vector reduce transfer ef®ciency and preclude repeated administration; (iii) some genes require a tightly regulated expression, so that achieving their balanced and functional expression becomes challenging; and (iv) it is dif®cult to deliver enough vector to the target cells to obtain a therapeutic effect. An alternative approach is to correct the genetic defect by targeting a dysfunctional exon, or the whole gene, directly substituting it with a correct copy by homologous recombination. The low frequency of homologous recombination in mammalian cells and the possibility of random insertion in the absence of sequence homology are major limitations to this approach (4). A novel technique, which exploits the DNA repair system of the cell, has recently been developed to correct genetic diseases that result from single-point mutations. This technique exploits the possibility of introducing site-speci®c changes in genomic DNA using oligonucleotides (5) . The molecules can be chemically modi®ed so that, upon pairing with the target sequence in the DNA, their chemically reactive group is activated and produces a modi®cation in the genome (6) . In this regard, RNA±DNA chimeric oligonucleotides have been designed to contain a sequence complementary to that of the target gene except for a single mismatched nucleotide. The unpaired nucleotide is apparently recognised by endogenous mismatch repair systems, thus altering the sequence of the target gene. This strategy has been successfully used to correct point mutations of a variety of genes, including human alkaline phosphatase (7, 8) , b-globin (9), factor IX (10) and UDP-glucuronosyltransferase-1 genes (11) . It is conceivable that, in the future, a similar approach could be exploitable in a large number of monogenic diseases resulting from single-point mutations, including endocrine diseases, such as congenital adrenal hyperplasia (CAH) due to 21-hydroxylase de®ciency.
Corrective gene therapy for monogenic endocrine diseases
The ®rst disease models for which gene therapy has been envisioned are those resulting from a single gene mutation that can be corrected by supplementing the functional gene. For many endocrine disorders, however, at variance with most inborn errors of metabolism (12) , gene therapy should restore not only the missing gene product, but also the intrinsic, strict regulation of native gene expression. Indeed, most hormones are secreted in a pulsatile fashion and show circadian rhythms. Regulated hormone delivery is essential to achieve optimal physiological effects.
Familial hypercholesterolaemia (FH)
FH has been one of the ®rst models of monogenic diseases for the development of human gene therapy. This metabolic disorder, caused by the inherited de®-ciency of the low density lipoprotein (LDL) receptor, is associated with severe hypercholesterolaemia and premature coronary artery disease. The homozygous form of FH is a good candidate for gene therapy, since it is a lethal disorder refractory to other treatments, such as LDL removal by aphoresis, or orthotopic liver transplantation. The ®rst gene therapy approach developed for FH was an ex vivo approach, using recombinant retroviruses carrying the LDL receptor gene to transduce hepatocytes, initially in animal models (13±15), then in humans (16, 17) . Treated patients showed long-term improvement of lipid pro®le without signs of toxicity. An in vivo approach, employing adenoviral vectors to transfer the LDL receptor gene, has been effective in lowering plasma cholesterol levels in mouse (18) and rabbit models (19, 20) (23) . Amelioration of lipoprotein pro®le in Watanabe rabbits was obtained also by adenovirus-mediated liver expression of apobec-1, the catalytic subunit of the enzyme complex which is responsible for the synthesis of apolipoprotein B48 (apoB48) mRNA following post-transcriptional editing of the apoB100 mRNA (24) . In rabbits, as well as in humans, the liver normally produces only apoB100 mRNA, being unable to edit endogenous hepatic apoB mRNA.
GH de®ciency
GH de®ciency is another candidate disease for gene therapy, since conventional treatment with GH requires frequent hormone administrations and shows decreased effectiveness with time. The dwarf little (lit/lit) mouse is a model for the human hereditary disorder of isolated GH de®ciency type I. This animal model has reduced serum levels of GH and insulin-like growth factor-I (IGF-I), due to an inactivating mutation of the GHreleasing factor receptor. One of the ®rst approaches for correcting the growth disorder in this mouse model was based on the injection of a metallothionein±rat GH fusion gene into eggs. Transgenic animals changed their phenotype to giants. Male animals showed improved fertility, whereas female fertility worsened (25) .
As an approach for gene therapy of GH de®ciency, genetically engineered myoblasts have been successfully used for GH delivery. The ®rst attempt employed myoblasts transduced by retroviral vectors encoding human GH (26) . After injection of transduced myoblasts into the murine muscle, human GH could be detected in serum for up to 3 months (26) . Implantation of microencapsulated allogenic myoblasts engineered to secrete murine GH into Snell dwarf mice increased linear growth and body weight of treated animals (27) . The allogenic myoblasts, which were protected from immune rejection by enclosure in microcapsules, remained functional for at least 6 months (27) . Surprisingly, when these encapsulated myoblasts were implanted into normal mice, the treated animals became signi®cantly shorter, lost weight and showed reduced skeletal growth (28) . Bioarti®cial muscles, i.e. tissue-engineered myoblasts organised into organlike structures, have been developed in order to ameliorate in vivo survival and fusion ef®ciency of tranduced myoblasts (29) . Subcutaneous bioarti®cial muscles secreting recombinant human GH were able to attenuate host skeletal muscle atrophy in a mouse model in which daily GH injections appeared to be ineffective (30) . Primary human skeletal muscle cells isolated from fetuses, normal adults and elderly patients with heart failure could be expanded, genetically modi®ed, and tissue-engineered into implantable bioarti®cial muscles secreting high levels of GH, similar to the murine skeletal myoblasts (31).
Muscle-speci®c enhancers/promoters have been used to produce biologically active GH or GH-releasing hormone in differentiated muscle cells (32±34). Even though muscle transcription elements can restrict gene expression to muscle ®bres (35) continuous GH secretion can cause organ hyperplasia (36, 37) . Ideally, a gene therapy strategy for GH de®ciency should mimic the physiological pulsatility of GH secretion. A controlled release of GH from skeletal muscle cells has been achieved following implantation of human ®bro-sarcoma cells into nude mice. These cells expressed two critical domains of a transcription factor as separate polypeptides that interact only in the presence of rapamycin. In cell culture, and in vivo upon transplantation of engineered cells into mice, expression of the therapeutic gene was inducible in a rapamycin dosedependent manner (38) . This system allowed long-term regulation of human GH expression when introduced into mice by i.m. injection of two separate adenoviral or AAV vectors, one encoding an inducible human GH gene, the other a bipartite rapamycin-regulated transcription factor (39) .
Besides myoblasts, other cell types can be used as GH delivery tools. In this respect, rabbit ®broblasts transfected with human GH cDNA were expanded in vitro and implanted under the renal capsule of nude mice, leading to stable delivery of GH for the life-time of the experimental animals (40) . A retroviral vector expressing the porcine GH cDNA was used to infect primary rat embryo ®broblasts. Transduced ®broblasts were injected into the peritoneum of syngeneic hypophysectomised rats (41) . Implanted cells could secrete biologically active GH in vivo, leading to signi®cant skeletal growth up to 57 days postimplantation (41) . Microencapsulation and other membrane encapsulation systems can be used to develop non-autologous transduced ®broblast cells for GH delivery (42, 43) . The use of keratinocytes for ex vivo gene therapy appears to be appealing since these cells can be easily propagated in culture and transferred into human skin. Human GH under the control of human keratin 14 promoter was ef®ciently produced, secreted, and released into the bloodstream of mice, at levels similar to the circulating GH concentrations in children (44) .
Autologous bone marrow stromal cells represent an alternative substrate for ex vivo GH-based gene therapy (45) . As for target tissues, the liver is an ideal metabolic factory that is also the natural target of adenoviral vectors. An adenoviral vector expressing rat GH cDNA was used to induce constitutive GH expression in hepatocytes of GH-de®cient lit/lit mice after systemic delivery (36) . Treated animals exhibited elevated serum GH values, with restored serum IGF-I concentrations, weight gain, increase in length and normalisation of body composition. Similar results were obtained following i.m. or i.v. injection, or instillation into the duct of the salivary glands of an adenoviral vector encoding the murine GH gene in GH-de®cient Snell dwarf mice (46) .
Hypothalamic diabetes insipidus
Hypothalamic diabetes insipidus may be caused by mutations in the arginine vasopressin (AVP) gene. AVP, the anti-diuretic hormone, is synthesised mainly within the supraoptic and paraventricular nuclei of the hypothalamus. After assessing the feasibility of adenovirusmediated transgene expression in the hypothalamus (47), Geddes et al. (48) developed a gene therapy approach for hypothalamic diabetes insipidus. They demonstrated that the stereotactical injection of an adenoviral vector encoding the AVP cDNA into the supraoptic nucleus of the Brattleboro rat, an AVPde®cient animal model of diabetes insipidus, resulted in long-term expression of the gene in magnocellular neurons (48) . AVP production was accompanied by reduced daily water intake and urine volume, as well as by increased urine osmolality lasting for up to 4 months. Transient expression of AVP in magnocellular neurons was also demonstrated following injection of naked AVP mRNA into the hypothalamus of Brattleboro rats (49) .
CAH
CAH is a group of diseases resulting from reduction or lack of activity of one of the enzymes that regulate cortisol synthesis in the adrenal cortex. Patients with CAH due to 21-hydroxylase de®ciency, the most commonly diagnosed enzyme de®ciency, cannot adequately synthesise cortisol and mineralocorticoids, leading to an excessive production of adrenocorticotrophin (ACTH) and adrenal androgens. Current treatment is based on steroid replacement, but problems relative to dose adjustment and patient compliance require the development of new therapeutic strategies. The disease is caused by mutations or deletions of the cytochrome P450 21-hydroxylase gene (CYP21). The feasibility of gene therapy for CAH was evaluated in a mouse model with deletion of the CYP21 gene (50) . An adenoviral vector carrying the human CYP21 gene under the control of the cytomegalovirus promoter was injected into the adrenal glands of 21-hydroxylasede®cient mice. The highest expression of CYP21 mRNA was observed 2±7 days after injection, followed by a gradual decline. 21-Hydroxylase activity and corticosterone production also reached levels similar to those found in normal mice. Adrenal morphological abnormalities of 21-hydroxylase-de®cient mice, i.e. lack of normal zonation and ultrastructural abnormalities of the mitochondria, were reduced 7 days after genetic treatment. A single intra-adrenal injection of the adenoviral construct did not elicit any immune response, suggesting that the in situ production of high levels of steroids has a protective effect, preventing induction of in¯ammatory responses (50) .
Gene therapy for multifactorial endocrine diseases
Although monogenic diseases were the initial focus of gene therapy, more recently multifactorial diseases, such as diabetes mellitus, cancer and cardiovascular disorders have been considered suitable for genetic intervention.
In this regard, cancer has become one of the most important targets of gene therapy. This development occurred not only because of the poor response shown by many tumours to conventional treatments, but also because of the modern view of cancer as a genetic disease at the somatic level, which implies a deeper understanding of the gene-related mechanisms of cell growth and oncogenesis. The role of the host immune system and the role of apoptosis in controlling tumour progression have been exploited to develop strategies that involve augmentation of immunotherapeutic and chemotherapeutic approaches.
Similarly, the comprehension of the role of genetic mechanisms in multifactorial disorders has favoured the concept that genetic modi®cation might be crucial for the design of new treatments. The pathogenesis of the most common diseases is characterised by an aetiological heterogeneity with the involvement of several genes, besides environmental factors. Such a complexity may hamper the development of genetic approaches to therapy as it was originally conceived for monogenic disorders. This is particularly true for some endocrine diseases, such as diabetes mellitus, which require restoration of the exquisite control of gene expression and response to signals of the pancreatic b-cells. The ®ne regulation of gene expression will also be essential in may other endocrine disorders which require the dif®cult task of introducing appropriate regulatory signals together with the missing gene.
Diabetes mellitus
Notwithstanding current protocols with diet therapy, insulin supplementation and oral anti-hyperglycaemic drugs, the sharp control of glycaemia, as well as of the long-term complications of the disease, is still problematic. Indeed, diabetes mellitus may be a candidate for a genetic treatment. Potential strategies for gene therapy of diabetes mellitus include: (i) prevention of the autoimmune destruction of b-cells, and thus of the onset of diabetes; (ii) correction of insulin de®ciency; and (iii) prevention of end-organ damages (51) .
Prevention of b-cell autoimmune destruction can be achieved by genetic modi®cation of either the b-cells or the immune cells (extensively reviewed in (52)).
A strategy to prevent islet damage by induction of tolerance was assessed in animal models of type I diabetes, which received intrathymic injection of islet extracts (53±55) or expressed a proinsulin transgene in the thymus in association with MHC class II molecules (56) .
b-Cell impairment and destruction in autoimmune diabetes is mediated in part by interleukin (IL)-1b, produced by immune cells. Gene transfer of the IL-1 receptor antagonist protein to cultured human islets prevented IL-1b-induced impairment of the response to a glucose challenge, as well as Fas-triggered apoptosis and nitric oxide production (57) . Alternative approaches envisage a reduction in the expression of major histocompatibility molecules (58) or the inhibition of co-stimulatory molecules, such as B7 or its ligand CD28. Indeed, prolonged survival of transplanted b-cells was observed upon engineering b-cells to express the fusion protein CTLA4-Ig, which contains cytotoxic T-lymphocyte-associated protein 4 and an IgG1 Fc portion, in order to block CD28±B7 interaction (59) .
b-Cells have also been engineered to secrete molecules that down-modulate the immune response, including IL-4 (60±63), IL-10 (64, 65), transforming growth factor (TGF)-b1 (65), the p40 subunit of IL-12 (66), anti-CD40 ligands (67) and the E3 region of adenoviruses (67) . Inhibition of cytokines that mediate the in¯ammatory response, such as interferon (IFN)-g and IL-12, may be a useful tool to treat autoimmune diabetes. To this purpose, i.m. injection of a non-viral vector encoding a soluble IFN-g receptor/IgG1 heavy chain fusion protein was shown to neutralise IFN-g and to prevent the onset of diabetes in experimental models (68) .
The transfer of genes encoding for molecules that interfere with the cytocidal activity of activated T-cells or with the apoptotic cascade occurring in b-cells has been explored as a therapeutic strategy for type I diabetes mellitus. FasL-expressing myoblasts co-transplanted with islets into allogeneic murine hosts signi®cantly prolonged islet survival by eliciting the death of activated T-cells that were highly expressing the Fas receptor (69) . At variance, FasL-expressing mouse b-cells were not protected in transgenic animals and in allografts (70, 71) , probably due to high susceptibility of pancreatic b-cells to Fas-mediated death (70, 72) . Better results were obtained with b-cells expressing soluble human FasL (73) .
Transduction of b-cells with the bcl2 gene protected them from apoptosis induced by pro-apoptotic cytokines in vitro (74) . Similarly, A20 gene transfer to rat islets protected against cytokine-induced apoptosis and cytokine-induced nitric oxide generation (75) .
Once b-cell loss has occurred, gene therapy may be employed to restore b-cell function, either by promoting b-cell regeneration or by assisting b-cell replacement. Endocrine pancreatic precursor cells have been demonstrated to persist even in overt diabetes (76) . Generation of b-cells from these precursors has been attempted by expression of a number of differentiation factors, including the vascular endothelial growth factor (VEGF) (77), the islet neogenesis-associated protein (78), the hepatocyte growth factor (79) The reconstitution of regulated insulin secretion in non-b-cells is a more dif®cult task. In this regard, glucose responsive promoters (i.e. pyruvate kinase and phosphoenolpyruvate carboxykinase promoters) may be employed to regulate the insulin gene transcription (92) . However, these promoters respond to insulin, besides glucose, and, therefore, may be less effective in diabetic people. Moreover, the kinetics of feedback loops based on transcriptional changes are much slower than that of the secretory response, with consequent problems of hypoglycaemia and hyperglycaemia.
An alternative to glucose-regulated insulin gene transcription is insulin-regulated release. Neuroendocrine cells, such as the mouse corticotrophic cell line AtT-20, have been engineered for diabetes mellitus gene therapy approaches, exploiting their secretory apparatus, which includes secretory granules and PC2 and PC3 endoproteases (86) . Introduction of the glucose transporter GLUT2 gene and of the glucokinase gene into these cells led to glucose-responsive insulin secretion (93) .
The (94) . In this regard, genetically modi®ed pigs have been produced to overcome xenograft hyperacute rejection (95) . To obtain an unlimited source of human pancreatic b-cells, several cell lines from the human fetal and adult pancreas have been developed by expression of dominant oncogenes, but the process of oncogenic transformation leads to dedifferentiation and raises the possibility that unregulated growth might occur in recipients (96) . Conditionally transformed b-cells, in which the expression of the oncogene is under the control of an inducible promoter (97) may be safer, even though the risk of changes during prolonged culture of the cell line remains a problem. Engineering human islet stem cells seems a more reasonable approach to overcome this hurdle (98, 99) . However, dedifferentiation and loss of insulin synthesis and regulated secretion, due to decreased GLUT2 and glucokinase levels, have been observed also with human islet cells after expansion in vitro (100). Improvements in the ability to culture pancreatic cells in vitro and to maintain the differentiated state might provide the solution to the problem of developing an unlimited source of b-cells for transplantation. Interesting results have been recently obtained with a human cell line developed from Langerhans islets isolated from a patient with a hyperinsulinaemic hypoglycaemia persisting from infancy (101), a neonatal disease characterised by dysregulation of insulin secretion. Engineering of this cell line by transfection with cDNAs encoding the K ATP channel and PDX1 repaired the genetic defects. A glucose-responsive human insulin-secreting cell line was thus obtained, which could be employed for treating the disease and for generating b-cell lines for cell therapy of diabetes mellitus (101) .
Obesity
Recent understanding of the molecular bases of obesity has allowed design of gene therapy approaches for this disease. Leptin, which is exclusively expressed in adipose tissue, is one of the factors that control satiety, as was demonstrated by the obese (ob/ob) mouse model, which lacks plasma leptin due to a nonsense mutation of the gene (102) . Daily administration of recombinant leptin to ob/ob mice was shown to induce weight reduction, appetite suppression, and decreased insulin and glucose blood levels (102±104). In the same animal model, a single injection of adenoviral vectors encoding the murine or the human leptin gene was more effective in accelerating weight reduction than a daily injection of recombinant protein. This result suggests that leptin effects are more prominent at the low steady-state levels which can be achieved by gene therapy (105±108). Hyperleptinaemia modi®ed the phenotype of adipocytes, with reduction of fat deposits, down-regulation of lipogenic enzymes and up-regulation of enzymes for fatty acid oxidation (109) . The use of helper-dependent adenoviral vectors, in which the sequences coding for the viral protein are completely eliminated, allowed a signi®cant improvement in safety and resulted in an ef®cient and long-term in vivo delivery of the leptin gene (110) . Recombinant AAV vectors may allow long-term expression of therapeutic genes in quiescent cells, such as muscle cells. A single i.m. injection of a recombinant AAV vector encoding mouse leptin in ob/ob mice led to long-term normalisation of metabolic abnormalities, including hyperglycaemia, insulin resistance, impaired glucose tolerance and lethargy (111) .
Autoimmune diseases
Endocrine glands are often targets of autoimmune diseases, resulting in either hormone hyperproduction or hypoproduction, which require adequate correction.
Non-speci®c immunosuppressive regimens, employed for some autoimmune disorders, are complicated by inherent side-effects, including an increased risk of infections and malignancies. Hence, the ideal therapeutic approach should be able to`silence' only the inappropriate immune response.
Many autoimmune diseases appear to be mediated by the T helper 1 (Th1) subset of CD4+ cells, which express the pro-in¯ammatory cytokines IFN-g, IL-2 and tumour necrosis factor-a. By contrast, regulation of autoimmunity appears to be mediated by Th2 cells, through the synthesis of the anti-in¯ammatory cytokines IL-4 and IL-10. Correcting the imbalance in the activities of Th1 and Th2 lymphocytes can be envisaged as the most appropriate therapeutic approach for some autoimmune disorders (112) .
Gene therapy has already been proposed in several animal models of autoimmune diseases to modify the disease course or just to evaluate the inherent treatment toxicity. The ®rst gene therapy trial for an autoimmune disease was started in 1997 in patients affected by rheumatoid arthritis after positive results had been demonstrated in animal models. The pilot study involved ex vivo retroviral infection of synoviocytes with a gene encoding the IL-1 receptor antagonist (IL-1Ra), which blocks IL-1-induced in¯ammation. Once the patient's synoviocytes were transduced and tested for absence of infectious contaminants, they were injected intra-articularly. The primary goal of the study was to assess safety, and, after analysis of IL-1Ra expression, patients underwent joint replacement (113) .
One of the great advantages of gene therapy for autoimmune diseases is the ability to deliver diseasemodifying proteins locally, avoiding systemic effects. Clinical trials employing the systemic administration of cytokines, antibodies and anti-receptor molecules, have produced clinical bene®t (114, 115) . However, such an approach can be complicated by emerging sideeffects, among which is generalised immunosuppression. In order to bypass this problem adoption of gene therapy in animal models has sought for effectiveness of the local secretion of`Th2-like' anti-in¯ammatory cytokines, such as IL-4 and IL-10, of regulatory cytokines like TGF-b, or of receptor antagonists like IL-1Ra. The antigen speci®city and migratory properties of memory T-cells allow them to serve as an endogenous system for delivering therapeutic transgenes to autoimmune lesions. Such an approach has already been used to treat the animal model of multiple sclerosis, i.e. the murine experimental allergic encephalomyelitis (116, 117) .
Fas±FasL interaction is required for the maintenance of the immune homeostasis. A failure in this interaction may lead to autoimmune and lymphoproliferative disorders (118, 119) . Autoreactive T-cells can be eliminated by transferring the gene encoding FasL. Transgenic mice with the FasL gene under control of the insulin promoter have been developed to give protection from insulin-dependent diabetes mellitus (70, 71) . However, as mentioned above, lack of protection was observed, probably due to high susceptibility of pancreatic b-cells to Fas-mediated death (70, 72) . On the contrary, mice with experimental autoimmune thyroiditis (a murine model of Hashimoto's thyroiditis, characterised by autoreactive T-and B-cell responses and marked lymphocytic in®ltration of the gland) showed regression of the disease upon treatment with plasmid DNA coding for FasL under the control of a thyroid-speci®c promoter (120) . Expression of FasL inhibited development of lymphocytic in®ltration of the thyroid and induced apoptosis of in®ltrating T-cells with total abrogation of the thyroglobulin (TG)-speci®c cytotoxic T-cell response. The role of gene therapy with FasL for autoimmune thyroiditis in humans remains to be elucidated, as Fas±FasL seems to play a pathogenic role in Hashimoto's thyroiditis (121) . A non-viral vector delivery of the IL-10 gene has also been employed in an attempt to treat mice affected by experimental autoimmune thyroiditis (122) . The rationale for this approach was given by the curative effects demonstrated by i.v. administration of IL-10 in this animal model (123) .
The future goal for gene therapy of endocrine autoimmune disorders is the identi®cation of the best gene, or combination of genes, to use in each disease and of the best system to obtain a long-lasting response.
Endocrine tumours
Current approaches for cancer gene therapy (124) can be divided into ®ve categories (Table 4) : transfer of genes with direct anti-tumour effects (including antisense oligonucleotides or ribozymes to inhibit oncogenes, or introduction of tumour suppressor genes or genes with anti-angiogenic effects); transfer of genes that activate drugs to their toxic form (suicide genes); transfer of genes that enhance the immune response against cancer (either by genetic modi®cation of tumour cells or by immune effector cells); and transfer of genes which decrease toxicity from chemotherapy, such as the multidrug resistance gene MDR1.
Corrective cancer gene therapy As for most cancers, endocrine tumours result from a multistep process, including loss of cell cycle control, neo-angiogenesis and evasion of immune control. Rarely, endocrine tumours occur as part of an inherited cancer syndrome, such as multiple endocrine neoplasia and the Li±Fraumeni syndrome. Most molecular abnormalities consist of the loss of putative tumour suppressor genes or of the activation of proto-oncogenes. Tumour suppressor genes regulate gene transcription and cell proliferation, and inactivation of both copies of the gene is needed to abrogate the anti-proliferative function. Thus, supplementation of a correct copy of the tumour suppressor gene in cells with homozygous loss of function could restore normal growth, induce tumour cell dormancy or apoptosis. At variance, mutation of only a single copy of a proto-oncogene is required for malignant transformation of a cell. Antisense oligonucleotides, ribozymes, and intracellular single-chain antibodies can be used to reduce the expression of oncogenes.
Gene therapy of cancer, in its most direct form, should aim at replacing a mutated gene with its correct form, or at suppressing the abnormal oncogenic function. At present, however, such a corrective gene therapy faces the insurmountable task that gene replacement, or gene suppression, should simultaneously involve a number of different genes, and should be applied to all tumour cells to reverse the malignant phenotype. Hence, corrective gene therapy seems to be quite dif®cult to propose as a single therapeutic approach.
Antisense gene therapy by the use of antisense oligonucleotides is aimed at suppressing the expression of a harmful gene, for example a proto-oncogene or a viral gene. Antisense oligonucleotides are short stretches of DNA (about 20 nucleotides in length) or modi®ed DNA that contain a base sequence complementary to a target RNA. By annealing to the target RNA, they interfere with its transport, splicing and translation. In some cases, the hybrid structure between antisense oligonucleotides and target molecules forms a substrate for cellular RNAses. Structural and chemical modi®cations of oligonucleotides (phophorothioate analogues being the most commonly used) have been developed to enhance af®nity and exonuclease resistance, and to reduce toxicity. Non-viral and viral vector systems have been employed to favour oligonucleotides delivery and/or intracellular production. Besides speci®c antisense effects, oligonucleotides may work via non-antisense mechanisms by binding to growth factors or to their receptors, thus interfering with cellular proliferation, an activity that can be exploited in cancer gene therapy.
Inhibition of target genes can be achieved also by ribozymes. Ribozymes are catalytic RNA molecules that recognise their target RNA in a sequence-speci®c manner and cleave the RNA strand. Ribozymes may be used as therapeutic tools because of their ability either to inhibit deleterious gene expression (oncogenes, viral transcripts) by cleavage of the target mRNA or even to repair mutant cellular mRNAs (125, 126) . There are several classes of ribozymes, with either cis-cleaving or trans-cleaving activity, among which are small pathogenic RNAs. These ribozymes contain different catalytic motifs (hammerhead, hairpin, axehead) and¯anking arms capable of base-pairing with the substrate. Since the arms of ribozymes that base-pair to substrate RNA are functionally separable from the moieties that effect cleavage, the substrate speci®city of ribozymes can be altered, within certain constraints, to allow trans-cleavage of target transcripts. Many of the problems raised by the employment of ribozymes are similar to those outlined for antisense oligonucleotides, i.e. ef®cient entry into the cell, stability and speci®city of substrate targeting.
Some endocrine-related tumours, such as breast and prostate cancer, have been targeted using antisense oligonucleotides or ribozymes. IGFs are important mitogens for a variety of tumour cells, including endocrine cancers and endocrine-related cancers (127) . An anti-IGF-I receptor antisense strategy has been successfully used against breast cancer cell lines (128) . Similarly, cleavage of IGF-II mRNA by a hammerhead ribozyme reduced prostate cancer cells growth (129) . Hammerhead ribozymes have also been designed to speci®cally cleave the androgen receptor mRNA (130) Table 4 Cancer gene therapy strategies. in prostate and breast cancer growth respectively. Transient transfection of prostate cancer cells with the androgen receptor ribozyme led to decreased activity and expression of androgen receptors, without deleterious side-effects (130) . Human MCF-7 breast cancer cells proliferation and entry into the S phase of the cell cycle decreased upon treatment with the oestrogen receptor-speci®c ribozyme (131) .
While oncogene alterations are usually dominant, tumour suppressor genes become tumorigenic through loss of function and tend to act in a recessive manner. p53 is the most commonly mutated tumour suppressor gene in human cancer and seems to play a prominent role in some endocrine tumours (132, 133) . Wild-type p53 protein is involved in G1 cell cycle arrest and apoptosis of DNA-damaged cells, and is therefore crucial in preventing mutation or deletion in functional genes. Restoration of wild-type p53 expression by the introduction of the wild-type p53 gene has recently been used in several cancer models and in human clinical trials of anti-cancer gene therapy (134) . Introduction of wild-type p53 in neoplastic cells can signi®cantly inhibit growth and angiogenesis or can induce apoptosis in a variety of p53 mutant cancer cells in vitro, including thyroid carcinomas (135±137). Since the presence of functional p53 has been shown to modulate chemoresistance, another possible advantage of the restoration of wild-type p53 may be sensitisation to chemotherapy and radiotherapy. Indeed, the combination of p53 gene transduction with radiation or chemotherapy resulted in an enhanced cytotoxic effect on thyroid carcinoma cell lines (137, 138) , even though the effectiveness of p53-based gene therapy was limited to cells carrying an inactive p53 (139).
The cell cycle regulator genes provide an additional target for corrective gene therapy. Among these, the p105Rb product of the retinoblastoma tumour suppressor gene (Rb) is one of the most critical regulators of cellular proliferation. The Rb protein, when unphosphorylated, is responsible for the cell cycle arrest by inhibition of the activity of the E2F family of transcription factors. Normal cell cycle progression requires inactivation of Rb through phosphorylation by cyclindependent kinases. In humans, Rb is inactivated in all familial and sporadic retinoblastomas, in 90% of small cell lung carcinomas, and in a variety of other tumours. Mice with a single wild-type copy of Rb (Rb =À ) develop Rb-de®cient melanotroph tumours of the pituitary intermediate lobe, and, in some cases, C-cell thyroid carcinomas and hyperplasia of the adrenal medulla (140, 141) . To evaluate the tumour suppressive potential of the wild-type Rb gene in vivo, a recombinant adenoviral vector expressing human Rb cDNA was delivered by direct injection into the pituitary intermediate lobe (142) . Intratumoural Rb transfer decreased tumour cell proliferation, re-established innervation by growth-regulatory dopaminergic neurons, and signi®cantly prolonged the life spans of treated animals compared with controls. Expression of a human Rb transgene in the Rb +/À mice suppressed tumour progression in a variety of tissues (143) . Moreover, the frequency of lung metastases in Rb +/À mice was reduced by repeated i.v. administration of Rb cDNA by non-viral vectors.
Restoration of other tumour suppressor genes expression, such as p16 and p27, may be employed to inhibit growth and to suppress tumorigenicity of endocrine neoplasms (144±147). Indeed, stable transfection of p16 in the mouse pituitary cell line AtT20, which carries a biallelic deletion of the p16 locus, arrested cells in the G1 phase and reduced cell proliferation (148).
Anti-angiogenic gene therapy Tumour growth and metastasis are dependent upon the ability of cancer cells to establish a blood supply through the process known as neoangiogenesis. This complex process is regulated by numerous factors, some being endowed with angiogenic properties, i.e. VEGF, platelet-derived growth factor-a, basic ®broblast growth factor (bFGF), epidermal growth factor and IL-8, while others act as endogenous inhibitors of angiogenesis, i.e. thrombospondin-1, platelet factor 4 (PF4), angiostatin and endostatin.
Anti-angiogenic therapies so far devised target different steps of the anti-angiogenic process, by inhibiting expression of angiogenic molecules, by overexpressing anti-angiogenic molecules, or by targeting tumour endothelial cells via endogenous angiogenic inhibitors or arti®cially constructed targeting ligands. Destruction of tumour vasculature can lead to tumour regression due to apoptosis (149) . Gene therapy has been advocated as a means to deliver anti-angiogenic factors to the tumour vasculature. It offers the advantage of high local production of factors with low systemic toxicity. Since the ®rst report of anti-angiogenic gene therapy with a dominant negative mutant of the VEGF receptor (150) , new important tools to suppress tumour growth and spread have been developed, which could be employed also for endocrine neoplasms. The main attempts are directed at: (i) suppressing expression of angiogenic factors with antisense oligonucleotides or ribozymes; and (ii) transferring genes that disrupt receptors for angiogenic factors (such as dominant negative functioning extracellular domains of the VEGF receptor¯t-1) or encode anti-angiogenic molecules, i.e. thrombospondin-1, PF4, angiostatin and endostatin (151) . Although many reports have established the ability of anti-angiogenic gene therapy to inhibit tumour growth and metastatic spread, this therapeutic approach often results in incomplete suppression of tumour growth and metastasis, and no tumour regression (151) . This problem may be circumvented in part with a combined gene therapy approach, employing different angiogenesis inhibitors together with cytokine or suicide genes.
Angiogenesis has been demonstrated to play an important role in tumour cell proliferation and in hormonal secretion of endocrine tumours. Thyroid neoplasms show an increased expression of angiogenic factors, including VEGFs (152±154) and angiopoietin-2, as well as their tyrosine kinase receptors (153) . In particular, overexpression of angiopoietin-2 and VEGF is associated with thyroid tumour progression from a prevascular to a vascular phase. Furthermore, thyroid cancers with lymph node spread show increased expression of VEGF-C, whereas aggressive tumours capable of haematogenous spread show a decreased production of trombospondin-1 (153) . A higher number of microvessels have been found in papillary thyroid carcinomas with distant recurrences. This ®nding, even if controversial, has been correlated with disease-free survival (153, 155, 156) . A correlation between microvessel count and prognosis has been suggested also for medullary thyroid carcinomas (156) . To investigate the role of VEGF in the angiogenetic process associated with the development of thyroid carcinomas, VEGF was stably transfected into a poorly tumorigenic cell line which expressed low basal levels of VEGF. As compared with parental cells, VEGFoverexpressing cells formed well-vascularised tumours when injected s.c. into nude mice (157) . Moreover, antisense suppression of VEGF expression in a highly tumorigenic anaplastic cell line led to the development of small and poorly vascularised tumours in vivo (157) . The feasibility of anti-angiogenic therapy to control the growth of anaplastic thyroid carcinomas has been demonstrated also with an inhibitor of angiogenesis in an animal model (158) .
Other endocrine tumours may become target of anti-angiogenic therapy. Indeed, angiogenesis plays an important role in the development of the adrenal cortex (159, 160) and in adrenocortical tumour cell proliferation (161) . Adrenocortical carcinomas seem to be associated with increased endothelial cell proliferation (161), whereas malignant phaeochromocytomas and paragangliomas show an increased number of intratumoural microvessels (162) .
The normal anterior pituitary is a well-vascularised tissue, whereas pituitary tumours are less vascular than normal pituitary tissue, suggesting that angiogenesis may be inhibited in these tumours (163, 164) . However, although these tumours are less vascular overall, they may have induced new vessel development from the systemic circulation, altering oxygen delivery and escaping hypothalamic in¯uences on hormone production (165±167). A series of vasogenic factors are expressed and produced within the pituitary gland, including some factors involved in angiogenesis (168) . Pituitary folliculostellate cells can produce both antiangiogenetic factors and angiogenetic factors, including VEGF (169) and bFGF (170) . These cytokines act in an autocrine/paracrine manner, and are regulated by hypothalamic factors, such as pituitary adenylate cyclase-activating polypeptide and IL-6 (171). Oestrogen-induced rat pituitary lactotroph tumours and rat pituitary GH/prolactin (PRL)-secreting GH3 tumour cell line overexpress VEGF and its co-receptor neuropilin-1 (172), suggesting a role in the modulation of pituitary tumour angiogenesis. Development of oestrogen-induced rat prolactinomas is also associated with increased expression of pituitary tumour transforming gene (PTTG) and bFGF (173) . A concomitant overexpression of PTTG and bFGF has also been demonstrated in human pituitary tumours (173) . As oestrogens and bFGF both induce PTTG, and PTTG expression coincides with the early stages of lactotroph cell transformation (from normal to hypertrophic cell), these factors may play a prominent role in pituitary tumorigenesis, and represent potential targets for therapeutic intervention (173) .
Suicide gene therapy Suicide gene therapy is de®ned as the use of a gene that converts a pro-drug into a toxic substance; independently, the gene product and the prodrug are non-toxic. The prototype of this approach exploits the requirement for the intracellular phosphorylation of GCV by the herpes simplex virus thymidine kinase gene product (HSV-TK). Activation generates a toxic drug metabolite that inhibits DNA synthesis, inducing cell death. The speci®city of the system can be increased by using tumour-speci®c promoters upstream of the suicide gene so that the gene is not transcribed within normal tissues. An interesting feature of the HSV-TK/GCV system is the`bystander' killing of non-transduced cells. The mechanisms that are responsible for this effect have not been fully de®ned, but are likely to include transfer of non-diffusible phosphorylated GCV to neighbouring cells through gap junctions, endocytosis by non-transduced cells of debris containing toxic GCV, and stimulation of host anti-tumour immune responses. A number of other suicide/prodrug systems have been employed. Among these are: E. coli cytosine deaminase that converts the relatively non-toxic 5-¯uorocytosine to the chemotherapeutic agent 5-¯uorouracil; cytochrome P-450 2B1 that catalyses cyclophosphamide conversion and ifosfamide activation; E. coli nitroreductase that converts 5-aziridinyl-2,4-dinitrobenzamide to a potent DNA crosslinking agent; and E. coli purine nucleoside phosphorylase that generates toxic purine nucleoside analogues (174) .
The effectiveness of suicide gene therapy has been explored in a variety of neoplasms, including endocrine tumours. The HSV-TK/GCV scheme was demonstrated to be effective against thyroid and pituitary tumours in cell cultures and in animal models. In this regard, human follicular and anaplastic thyroid carcinoma cell lines, transduced with a retroviral vector containing HSV-TK under the control of the cytomegalovirus promoter, were killed by GCV in a dose-and timedependent manner. Tumour regression was also observed in nude mice. A bystander effect and radiosensitisation were documented in vitro and in vivo (175) . To develop thyroid-speci®c retroviral vectors the bovine TG promoter was introduced to control suicide gene expression (176) . Selective killing of TG-producing cells was observed upon GCV treatment (176) . A synthetic tandemly repeated TG promoter seemed to enhance promoter activity (177) . Another strategy to improve TG promoter activity exploited the use of the Cre-loxP system (178) . To this end, two recombinant adenoviral vectors were used, one with the Cre recombinase gene under the control of the TG promoter, the other with a stuffer sequence,¯anked by the loxP sequences and including the neo-resistance gene. The latter gene was placed between the strong chimeric CAG promoter and the HSV-TK gene. In this system, the Cre recombinase is expressed when the TG promoter is active, thus removing the stuffer sequence and inducing HSV-TK expression under the transcriptional control of the CAG promoter. The cytotoxic effect of HSV-TK/GCV obtained in vitro with the TG promoter and the Cre-loxP system was 5-to 10-fold higher than that obtained with the TG promoter alone. Enhanced tumour growth inhibition was also observed in in vivo tumour models (178) .
A tissue-speci®c approach was attempted also for medullary thyroid carcinomas, exploiting the promoter sequence of the calcitonin gene to drive selective expression of HSV-TK in tumour cells injected in vivo, with reduced side-effects (179) .
Adenoviral vectors have been demonstrated to be effective and safe delivery vehicles for the pituitary gland (3, 180±185). Adenoviral vectors were employed to transduce pituitary adenoma cell lines and animal models with HSV-TK (181, 186) . Cell-type-speci®c expression of the therapeutic gene was achieved using the promoters of the GH, glycoprotein hormone a-subunit, and PRL genes (181, 187) . In addition to cell-type-speci®c expression of the therapeutic gene, regulation of transgene expression is foreseeable for gene therapy of many endocrine disorders. The tetracycline-inducible system, which allows gene expression to be regulated by the tetracycline analogue doxycycline, has been used to develop a PRL-speci®c and regulatable adenoviral vector (188, 189) . By driving the expression of the tetracycline transactivator through the PRL-speci®c promoter, expression of the inducible transgene was restricted to both lactotrophic tumour cell lines and PRL-positive cells in primary anterior pituitary cultures (188, 189) .
Targeting therapeutic genes to speci®c cell types is particularly relevant for pituitary adenoma gene therapy in order to spare normal pituitary cells and neighbouring tissues. This aim could be also achieved by retargeting viral vector tropism so that the vectors recognise and bind pituitary-speci®c surface molecules, such as hypothalamic hormone receptors, which are often overexpressed in pituitary tumours (190, 191) .
Recombinant temperature-sensitive HSV type 1 vectors have been employed for gene transfer into tumours and normal anterior pituitary cells (192) . However, neurovirulence of this vector system limits its potential use for gene therapy in humans, even though it can be used as a delivery system to generate transient transgenesis for biological studies (193) .
Transcriptionally targeted gene therapy is feasible also for other endocrine cancers, exploiting cis-acting regulatory sequences of tissue-speci®c genes. Promoter/ enhancer elements of steroidogenetic enzymes could be employed to target transgene expression in steroidsecreting cells. A chimeric enhancer/promoter element, containing both the CYP11B1 promoter and the P450SCC enhancer was employed to target HSV-TK expression in adrenocortical carcinoma cells. HSV-TK expression and GCV sensitivity of stably transfected adrenal cancer cells was enhanced by treatment with factors acting through the cAMP pathway, such as ACTH (194) .
A limitation for targeted gene therapy approaches employing enhancer/promoter elements of genes expressed by differentiated cells, such as hormones, receptors or enzymes, is the risk of decreased transgene expression in tumour cells due to dedifferentiation. To overcome this problem, regulatory sequences of genes that are highly and speci®cally expressed in malignant cells, such as IGF-II in adrenocortical carcinomas (195) or oncofetal ®bronectin in thyroid carcinomas (196) , should be employed.
The iodide-concentrating ability of thyroid cells, which is based on the tissue-speci®c expression of the sodium/iodide symporter gene (NIS), allows for diagnostic radionuclide thyroid imaging with 123 I and 99m Tc. Radioiodine therapy of differentiated thyroid carcinomas using 131 I can also be pursued, with minimal systemic side-effects, except for the need for replacement therapy. The rat NIS has been transferred into cancer cells by a retroviral vector to mimic the iodide uptake of thyroid follicular cells. NIS-mediated accumulation of 123 I by transduced cancer cells allowed scintigraphic detection of tumours in vivo. Selective killing of NIS-transduced cells by the induced accumulation of 131 I was demonstrated in vitro (197) . Thus, NIS-based gene therapy may have both diagnostic and therapeutic applications for cancer.
Morbidity and mortality of patients with endocrine tumours are often due more to hormone overproduction rather than to metastatic disease. In some cases refractory to conventional surgical and pharmacological treatment, such as Cushing's syndrome, acromegaly and endocrine pancreatic tumours, gene therapy may be an effective approach. In this regard, human lactotroph adenoma cells have been transduced with an adenoviral vector encoding tyrosine hydroxylase, a rate-limiting enzyme in the biosynthesis of dopamine, in an attempt to decrease PRL release (3). A similar approach could be used for other types of tumours. For example, GH-secreting adenomas could be treated with somatostatin gene transfer.
Immunomodulating gene therapy Immunomodulating gene therapy has been developed in an attempt to stimulate cellular immune responses against tumourspeci®c antigens. One method is to genetically modify the tumour cell to have it express cytokines (e.g. IL-2, IL-12, granulocyte-macrophage colony-stimulating factor, or IFN-g) that attract antigen-presenting cells such as dendritic cells and macrophages, and to activate a systemic T-cell immune response. Another method is to genetically modify the tumour cell itself to become a professional antigen-presenting cell through the expression of MHC molecules, co-stimulatory molecules such as B-7, and cytokines genes necessary for T-cell activation and proliferation. To avoid costly and timeconsuming processes involved in generating tumour vaccines by ex vivo approaches, in vivo strategies to enhance immune response have been developed, such as vector-mediated delivery of cytokine genes.
Another immunological approach involves the use of vectors for the expression of tumour-associated antigens (vaccines). Recombinant vaccines may be either viral, bacterial or`naked' DNA (198) . Recombinant viral vaccines offer the advantage of intrinsic immunogenicity, whereas bacterial vaccines have cellular tropism for monocytes and macrophages, and possess enteric routes of infection, providing the possibility of oral delivery (198) .`Naked' DNA vaccines, which can persist and express encoded genes for long periods of time after i.m. injection, have been demonstrated to mediate both antibody-mediated and cellular immune responses against encoded gene products, even if they are less potent than other recombinant vaccines (199) .
Another potential method of manipulating the immune response against cancer is to utilise dendritic cells (200) , which are highly potent antigen-presenting cells capable of stimulating and activating quiescent lymphocytes. Stable introduction of tumour-antigen genes into dendritic cells may allow presentation of multiple immunogenic epitopes of the same antigen, as well as the constitutive expression of the antigen in vivo. In addition, introduction of cytokine genes into dendritic cells may enhance the anti-tumour response.
Genetic immunotherapy showed interesting results in a model of medullary thyroid carcinoma in vitro and in vivo. In vitro infection of murine medullary thyroid carcinoma cells with an adenoviral vector harbouring the mouse IL-2 gene abrogated their tumorigenicity and induced a long-lasting state of immunity in syngeneic BALB/C mice (201) . In vivo, intratumour injection of the adenoviral vector resulted in the rejection and/or stabilisation of pre-established tumours in treated mice (202) without signi®cant toxicity to other organs (203) .
Combined gene therapy approach A new treatment strategy combining two different modalities, enzymedirected prodrug activation (tumour suicide) along with cytokine-promoted tumour rejection, has been recently devised to amplify the anti-tumour response, and proved to be ef®cacious in animal models (204) . A bicistronic retroviral vector co-expressing HSV-TK and human IL-2 genes has been designed to pursue this new approach of cancer gene therapy in humans (205, 206) and successfully employed in a pilot study to treat four patients with recurrent glioblastoma multiforme (207, 208) . A similar construct has been developed to treat human thyroid carcinomas. In this regard, the HSV-TK and human IL-2 genes, separated by an internal ribosome entry site to allow the simultaneous expression of the two genes from the same transcript, were cloned into the MFG retroviral vector. Transcriptionally targeted thyroid-speci®c vectors were generated replacing the viral enhancer in the long terminal repeat with the enhancer sequence of the human TG gene (209) . In vitro experiments showed selective killing of transduced thyroid carcinoma cells by GCV treatment, and secretion of biologically active IL-2. Such a combined approach, employing both cytokine and suicide genes, seems to elicit a potentiated anti-cancer effect in vivo, as observed in a mouse model of medullary thyroid carcinoma inoculated with both HSV-TK-transduced carcinoma cells and IL-2-transfected cells (210) .
Conclusions
Scienti®c progress in biomedical research has revealed the molecular mechanisms of many human diseases. Although several endocrine disorders are caused by the inheritance of a single, functionally defective gene, the molecular bases of most endocrine diseases relate to acquired genetic defects. These defects would eventually require an aetiological (non-pharmacological) genetic intervention. Present premises seem to favour intervention for endocrine tumours, but many combined approaches of cell and gene therapy are foreseeable also for endocrine and metabolic disorders.
